0.71 USD
▼-0.00-0.35%
盘后 0.89 0.00%
2026-09-16
市值
$60.57M
市盈率
—
EPS
-1.30
股息率
—
52 周区间
0.69 – 2.18
成交量
187.41K
Beta
1.37
目标价
6.00
52W 低 0.6952W 高 2.18
价格走势
公司简介
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs ...